Success Story: Advancing Retinal Imaging Biomarkers for Vision Care: NIW Approval Secured for an Ophthalmology Researcher from Turkey
Client’s Testimonial:
“You were professional and meticulous with the process. Thanks a lot!”
On August 31st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Visiting Research Scholar (Research Fellow) in the field of Ophthalmology (Approval Notice).
General Field: Ophthalmology
Position at the Time of Case Filing: Visiting Research Scholar (Research Fellow)
Country of Origin: Turkey
State of Residence at the Time of Filing: California
Approval Notice Date: August 31st, 2026
Processing Time: 2 months, 1 day (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of an ophthalmology researcher whose work advances precision diagnosis and treatment monitoring for retinal diseases. The client’s proposed endeavor focuses on developing quantitative retinal imaging biomarkers using multimodal retinal imaging, optical coherence tomography, automated segmentation, and statistical modeling to improve characterization of retinal disease activity and treatment response. At the time of filing, the client was conducting research in ophthalmology, focusing on retinal imaging, quantitative biomarkers, and data-driven approaches for improving vision care.
Research with National Importance
The client’s research addresses critical challenges in ophthalmic care by improving the accuracy and scalability of retinal disease evaluation. Through advanced imaging analysis and biomarker development, her work supports earlier detection, improved treatment assessment, and more informed clinical decision-making for vision-impairing diseases. These contributions align with U.S. priorities in vision research, healthcare innovation, and data-driven medical technologies.
Academic Contributions and Recognition
At the time of filing, the client had authored 19 peer-reviewed journal articles (3 first-authored and 1 co-first-authored), 14 conference abstracts (1 first-authored), and 1 preprint. Her work received 781 citations, demonstrating recognition from researchers in ophthalmology, population health, and related biomedical fields. Her publications appeared in highly regarded journals, including The Lancet, Ophthalmology Retina, Investigative Ophthalmology & Visual Science, and American Journal of Ophthalmology. Two publications ranked among the top 0.01% most cited articles in Clinical Medicine, with additional publications ranking among the top 10% and top 20% most cited articles for their respective years of publication. She has also completed peer reviews for journals in related fields, reflecting recognition of her expertise by the research community.
Recognition from Experts
Experts highlighted the importance of the client’s contributions to advancing retinal imaging technologies and improving clinical decision-making in ophthalmology.
“The importance of [client]’s research to retinal disease monitoring, treatment planning, and vision-preservation strategies is evident, given the breakthroughs that her research has fostered in these areas and in the field of ophthalmology more generally. Ensuring that [client]’s work proceeds is thus not only important to the field, but to the United States as well.”
This endorsement reinforces the significance of the client’s contributions to ophthalmology and retinal disease research. Combined with her publication record, citation impact, peer review activities, and research influence, the expert support further demonstrates her ability to advance quantitative retinal imaging approaches for vision care.
NIW Approval and Outlook
The I-140 NIW petition was filed on June 30th, 2026, with Direct Premium Processing, and approved on August 31st, 2026. The approval recognized the national importance of the client’s work in ophthalmology, particularly her efforts to develop quantitative retinal imaging biomarkers to improve retinal disease diagnosis and treatment assessment.
This outcome supports the client’s continued efforts to advance retinal imaging technologies, improve diagnostic precision, and contribute to innovative approaches for treating vision-impairing diseases in the United States. We congratulate her on this approval and wish her continued success in advancing ophthalmic research.